{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:55:46Z","timestamp":1781664946524,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.vaccine.2025.127916","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:29:53Z","timestamp":1762212593000},"page":"127916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants"],"prefix":"10.1016","volume":"68","author":[{"given":"Shelly","family":"Senders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Korbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Tamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Drozd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Trammel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanyu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"McElwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127916_bb0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127916_bb0010","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127916_bb0015","doi-asserted-by":"crossref","unstructured":"GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018;18:1191\u2013210. doi:https:\/\/doi.org\/10.1016\/S1473-3099(18)30310-4.","DOI":"10.1016\/S1473-3099(18)30310-4"},{"key":"10.1016\/j.vaccine.2025.127916_bb0020","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1016\/j.vaccine.2020.08.068","article-title":"Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis","volume":"38","author":"Chapman","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127916_bb0025","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.127916_bb0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12879-015-1147-x","article-title":"Pneumococcal serotype evolution in Western Europe","volume":"15","author":"Tin Tin Htar","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127916_bb0035","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children\u2014use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Nuorti","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2025.127916_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177113","article-title":"Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis","volume":"12","author":"Balsells","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127916_bb0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/21645515.2015.1118593","article-title":"Interim results of an ecological experiment - conjugate vaccination against the pneumococcus and serotype replacement","volume":"12","author":"Hausdorff","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127916_bb0050","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1016\/j.vaccine.2022.06.024","article-title":"Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States","volume":"40","author":"Huang","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127916_bb0055","doi-asserted-by":"crossref","first-page":"e1062","DOI":"10.1093\/cid\/ciac475","article-title":"Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination","volume":"76","author":"Grant","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127916_bb0060","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1016\/j.vaccine.2019.08.048","article-title":"Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults","volume":"37","author":"Thompson","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127916_bb0065","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127916_bb0070","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1016\/j.vaccine.2021.10.032","article-title":"A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults \u226565 years of age with different prior pneumococcal vaccination","volume":"39","author":"Cannon","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127916_bb0075","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127916_bb0080","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/INF.0000000000003277","article-title":"Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants in the United States","volume":"40","author":"Senders","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127916_bb0085","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/INF.0000000000004334","article-title":"A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants","volume":"43","author":"Senders","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127916_bb0090","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000004300","article-title":"Phase 3 safety and immunogenicity study of a three-dose series of twenty-valent pneumococcal conjugate vaccine in healthy infants and toddlers","author":"Korbal","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127916_bb0095","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged >\/=18 years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127916_bb0100","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/cid\/ciw067","article-title":"Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine","volume":"62","author":"Tomczyk","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127916_bb0105","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.cmi.2015.08.027","article-title":"Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA","volume":"22","author":"Metcalf","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.127916_bb0110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/cid\/cix310","article-title":"Childhood deaths attributable to invasive pneumococcal disease in England and Wales, 2006-2014","volume":"65","author":"Oligbu","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127916_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000081","article-title":"Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study","volume":"6","author":"Harboe","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2025.127916_bb0120","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/cid\/ciaa917","article-title":"Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation","volume":"72","author":"Cohen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127916_bb0125","author":"PREVNAR"},{"key":"10.1016\/j.vaccine.2025.127916_bb0130","unstructured":"Product Monograph PREVNAR 20, Pfizer Canada ULC, https:\/\/www.pfizer.ca\/files\/Prevnar-20_PM_EN_270922_21-July-2023.pdf; 2023 [accessed August 16, 2023]."},{"key":"10.1016\/j.vaccine.2025.127916_bb0135","unstructured":"Apexxnar (pneumococcal polysaccharide conjugate vaccine [20-valent, adsorbed]). Summary of product characteristics, Pfizer Europe, Bruxelles, Belgium, 2022."},{"key":"10.1016\/j.vaccine.2025.127916_bb0140","author":"ECDC Vaccine Scheduler"},{"key":"10.1016\/j.vaccine.2025.127916_bb0145","unstructured":"Prevenar 20 Brazil National Health Surveillance Agency, https:\/\/consultas.anvisa.gov.br\/#\/bulario\/detalhe\/3614064?nomeProduto=Prevenar%C2%AE%2020; 2024 [accessed 23 October 2024."},{"key":"10.1016\/j.vaccine.2025.127916_bb0150","author":"Therapeutic Goods Administration Australia"},{"key":"10.1016\/j.vaccine.2025.127916_bb0155","unstructured":"Kroger A BL, Long S, Sanchez P. General Best Practice Guidelines for Immunization, https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/downloads\/general-recs.pdf; [accessed April 7, 2025]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:23:10Z","timestamp":1781662990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25012137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"alternative-id":["S0264410X25012137"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127916","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127916"}}